Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.09
Percentage change 0.78	%

Peers: JNJ ALGN NVO TEVA PFE MRK CRL DHR ABT EXAS

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	89.68%	Shs Outstand	353.36M	Perf Week	2.01%
Market Cap	4.13B	Forward P/E	15.26	EPS next Y	0.77	Insider Trans	0.01%	Shs Float	36.48M	Perf Month	2.63%
Income	-362.00M	PEG	-	EPS next Q	0.07	Inst Own	9.85%	Short Float	7.08%	Perf Quarter	-27.33%
Sales	4.83B	P/S	0.86	EPS this Y	-28.63%	Inst Trans	7.91%	Short Ratio	3.09	Perf Half Y	-40.52%
Book/sh	18.00	P/B	0.65	EPS next Y	70.47%	ROA	-2.71%	Short Interest	2.58M	Perf Year	-22.92%
Cash/sh	0.61	P/C	19.23	EPS next 5Y	17.07%	ROE	-5.56%	52W Range	10.45 - 21.69	Perf YTD	-35.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-3.25%	52W High	-46.06%	Beta	0.56
Dividend TTM	-	Quick Ratio	0.96	Sales past 5Y	4.87%	Gross Margin	54.21%	52W Low	11.96%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	1.56	EPS Y/Y TTM	-6.98%	Oper. Margin	3.23%	RSI (14)	48.35	Volatility	0.35% 2.36%
Employees	13500	Debt/Eq	0.76	Sales Y/Y TTM	11.94%	Profit Margin	-7.50%	Recom	2.44	Target Price	14.04
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	-26.32%	Payout	-	Rel Volume	0.53	Prev Close	11.61
Sales Surprise	-1.16%	EPS Surprise	-433.33%	Sales Q/Q	3.46%	Earnings	Apr 30 BMO	Avg Volume	835.61K	Price	11.70
SMA20	1.08%	SMA50	-3.62%	SMA200	-29.04%	Trades		Volume	446,944	Change	0.78%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Reiterated	H.C. Wainwright	Buy	$20 → $15
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $15
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$24 → $22
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform	$19 → $25
Jul-10-24	Initiated	Raymond James	Outperform	$19
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$16 → $18
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line	$19 → $17
Dec-12-23	Initiated	Stifel	Hold	$16
Oct-03-23	Resumed	Evercore ISI	Outperform	$20
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$20
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight	$17
Sep-12-22	Initiated	H.C. Wainwright	Buy	$21
Jul-26-22	Initiated	RBC Capital Mkts	Outperform	$22
Jun-24-22	Initiated	Evercore ISI	Outperform	$21
Jun-06-22	Initiated	Citigroup	Buy
May-31-22	Initiated	Wells Fargo	Overweight	$23
May-31-22	Initiated	Morgan Stanley	Equal-Weight	$22
May-31-22	Initiated	JP Morgan	Neutral	$20

Show Previous Ratings

Jun-04-25 06:59AM	Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States (Business Wire)
May-27-25 12:47PM	Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know (StockStory)
May-22-25 07:30AM	Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
12:00AM	3 Reasons to Avoid BLCO and 1 Stock to Buy Instead (StockStory)
May-21-25 04:30PM	Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results (Business Wire)
09:36AM	Loading…
09:36AM	Anthony Pompliano on taking his SPAC public: Focused on buying a cash-flow positive business (CNBC TV)
06:59AM	Bausch + Lomb Launches New LUMIFY Preservative Free Redness Reliever Eye Drops in the United States (Business Wire)
May-14-25 06:59AM	Bausch + Lomb Launches Zenlens CHROMA HOA in the United States (Business Wire)
May-08-25 12:37AM	3 Profitable Stocks Walking a Fine Line (StockStory)
May-07-25 09:30AM	Bausch + Lomb gets European nod for intraocular lens (Seeking Alpha)
07:00AM	Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens (Business Wire)
May-01-25 03:08AM	Bausch & Lomb Corp (BLCO) Q1 2025 Earnings Call Highlights: Navigating Growth Amid Challenges (GuruFocus.com)
Apr-30-25 04:40PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -15.74%
11:02AM	Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Loading…
08:10AM	Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:57AM	Bausch + Lomb Announces First-Quarter 2025 Results (Business Wire)
Apr-29-25 03:10AM	Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings (StockStory)
Apr-24-25 10:01AM	CVS Health (CVS) Earnings Expected to Grow: Should You Buy? (Zacks) +9.03%
07:00AM	Bausch + Lomb Returning enVista Intraocular Lenses to Market Following Voluntary Recall (Business Wire)
Apr-23-25 07:23PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
11:40AM	BLCO or DHR: Which Is the Better Value Stock Right Now? (Zacks)
10:01AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-22-25 10:08AM	Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-21-25 04:39PM	Bausch Health Companies Inc (BHC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
07:00AM	Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue Eye Care Recycling Programs (Business Wire)
Apr-18-25 05:16AM	3 Reasons to Sell BLCO and 1 Stock to Buy Instead (StockStory)
Apr-13-25 12:47AM	PCMM: Why This Private Credit ETF Deserves A Spot On Your Watchlist (Seeking Alpha)
Apr-10-25 09:05AM	Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? (Zacks) -9.66%
Apr-08-25 06:46PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -7.33% +13.91%
05:02AM	Loading…
Apr-07-25 05:02AM	Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment (StockStory)
Apr-03-25 03:39PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -9.48%
Mar-28-25 02:33PM	Bausch + Lomb Stock Sinks on 'Voluntary Recall' of Some Implantable Eye Lenses (Investopedia) -5.80%
01:33PM	Mag 7 slide, gold rises, Bausch + Lomb recall: Market Minute (Yahoo Finance Video)
01:20PM	Why Bausch + Lomb (BLCO) Shares Are Plunging Today (StockStory)
Mar-27-25 02:54PM	Why Bausch + Lomb (BLCO) Stock Is Nosediving (StockStory)
07:00AM	Bausch + Lomb Announces Voluntary Recall of enVista Aspire, enVista Envy and Certain enVista Monofocal Intraocular Lenses (Business Wire)
Mar-26-25 07:45AM	Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30 (Business Wire)
Mar-17-25 07:00AM	Bausch + Lomb Launches Arise Orthokeratology Lens System in the United States (Business Wire)
Feb-23-25 02:00PM	How DOGE's 'transparency' could be applied to healthcare (Yahoo Finance Video)
Feb-20-25 02:41AM	Q4 2024 Bausch + Lomb Corp Earnings Call (Thomson Reuters StreetEvents)
02:03AM	Bausch & Lomb Corp (BLCO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-19-25 01:22PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
08:53AM	Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent (Yahoo Finance)
07:51AM	Bausch + Lomb to shake up contact lenses with deal off the table (Yahoo Finance Video)
07:21AM	Bausch + Lombs (NYSE:BLCO) Q4: Beats On Revenue (StockStory)
06:58AM	Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance (Business Wire)
04:28AM	Bausch & Lomb Corp (TSX:BLCO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-18-25 08:03AM	Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-06-25 07:17PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -9.52%
07:00AM	Bausch + Lomb Provides Update on Potential Sale (Business Wire)
Jan-22-25 07:00AM	Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 (Business Wire)
Jan-13-25 07:00AM	Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences (Business Wire)
06:00AM	Bausch + Lomb Launches enVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union (Business Wire)
Jan-12-25 09:30AM	Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-07-25 07:00AM	Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual Faces of Glaucoma Campaign and Fundraising Challenge (Business Wire)
Jan-03-25 06:46AM	Bausch + Lomb price target lowered to $22 from $25 at Evercore ISI (TipRanks)
Jan-02-25 07:00AM	Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 10:45AM	BofA rates Bausch & Lomb underperform with lower buyout chances (Investing.com)
Dec-12-24 07:00AM	Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb (ACCESSWIRE)
07:00AM	Bausch + Lomb Responds to Rumors of a Potential Sale (Business Wire)
Dec-11-24 02:14PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -12.06%
06:59AM	Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities (Business Wire)
Nov-22-24 02:31PM	Bausch & Lomb Corporation (BLCO)-A Bull Case Theory (Insider Monkey)
02:31PM	Bausch and#038; Lomb Corporation (BLCO)-A Bull Case Theory (Insider Monkey)
Nov-14-24 07:00AM	Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue Eye Care Recycling Programs (Business Wire)
Oct-31-24 03:06AM	Bausch & Lomb Corp (BLCO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-30-24 05:52PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
07:00AM	Bausch + Lomb Announces Third-Quarter 2024 Results (Business Wire)
Oct-29-24 09:05AM	Bausch & Lomb Corp (TSX:BLCO) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-23-24 09:45AM	Bausch + Lomb price target raised to $23 from $20 at RBC Capital (TipRanks)
Oct-14-24 11:38AM	Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid (Investopedia) +7.19%
10:57AM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
07:00AM	Bausch + Lomb Receives FDA Approval for enVista Envy Full Range of Vision Intraocular Lens (Business Wire)
Oct-09-24 08:00AM	Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 (Business Wire)
Oct-02-24 08:40AM	Bausch + Lomb price target raised to $19 from $17 at Evercore ISI (TipRanks)
Oct-01-24 07:00AM	Bausch + Lomb Launches Opal Digital Marketplace in the United States (Business Wire)
Sep-18-24 11:01AM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) +7.76%
Sep-16-24 06:35PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) +14.47%
12:26PM	Bausch + Lomb Stock Jumps Amid Reports Of A Sale (Investopedia)
09:52AM	Stocks to Watch Monday: DJT, Apple, Pfizer, Intel (The Wall Street Journal)
07:22AM	Bausch + Lomb explores sale amid parent company's debt woes - report (Investing.com)
Aug-07-24 11:37PM	Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp (GuruFocus.com)
Aug-05-24 06:45PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -5.70%
Aug-01-24 10:41AM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Jul-31-24 03:55PM	Bausch + Lomb CEO Brent Saunders on growth opportunities (CNBC TV)
12:08PM	Bausch + Lomb CEO on strength in eye care, competitive positioning (CNBC TV)
07:00AM	Bausch + Lomb Announces Second-Quarter 2024 Results (Business Wire)
Jul-30-24 06:33PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Jul-25-24 06:33PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Jul-24-24 06:24PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -5.05%
Jul-17-24 06:53PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Jul-11-24 12:05PM	Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31 (Business Wire)
Jul-08-24 07:00AM	Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief (Business Wire)
Jun-17-24 07:00AM	Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress (Business Wire)
Jun-10-24 07:00AM	Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States (Business Wire)
Jun-03-24 07:00AM	Bausch + Lomb Launches Blink NutriTears Clinically Proven Nutritional Supplement for Dry Eyes in the United States (Business Wire)
May-29-24 04:30PM	Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results (Business Wire)
May-28-24 09:00AM	Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometrys Meeting (Business Wire)
06:59AM	Bausch + Lomb Receives Health Canada Approval for enVista Envy* Full Visual Range Intraocular Lens (Business Wire)

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAUNDERS BRENT L	CEO and Chairman of the Board	May 22 '25	Buy	11.28	22,000	248,072	719,156	May 27 08:16 AM
VON ESCHENBACH ANDREW C.	Director	May 02 '25	Buy	11.76	1,695	19,925	41,748	May 06 04:30 PM
SAUNDERS BRENT L	CEO and Chairman of the Board	Aug 05 '24	Buy	15.66	32,250	505,067	595,169	Aug 07 05:29 PM

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Jun 06 • 04:00PM ET

14.49

Dollar change +1.05
Percentage change 7.81	%

Healthcare • Biotechnology • USA • NASD

SPRY ARS Pharmaceuticals Inc daily Stock Chart

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA FYC FYX

Index	RUT	P/E	-	EPS (ttm)	-0.16	Insider Own	44.24%	Shs Outstand	98.13M	Perf Week	0.42%
Market Cap	1.42B	Forward P/E	-	EPS next Y	-0.71	Insider Trans	-2.51%	Shs Float	54.77M	Perf Month	7.41%
Income	-15.65M	PEG	-	EPS next Q	-0.47	Inst Own	53.75%	Short Float	33.29%	Perf Quarter	33.55%
Sales	97.12M	P/S	14.65	EPS this Y	-1939.16%	Inst Trans	12.02%	Short Ratio	10.67	Perf Half Y	6.47%
Book/sh	2.33	P/B	6.21	EPS next Y	51.80%	ROA	-5.64%	Short Interest	18.23M	Perf Year	62.08%
Cash/sh	2.81	P/C	5.16	EPS next 5Y	55.23%	ROE	-6.91%	52W Range	7.55 - 18.51	Perf YTD	37.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-6.83%	52W High	-21.72%	Beta	0.83
Dividend TTM	-	Quick Ratio	10.74	Sales past 5Y	-	Gross Margin	97.66%	52W Low	91.92%	ATR (14)	0.84
Dividend Ex-Date	-	Current Ratio	11.00	EPS Y/Y TTM	68.69%	Oper. Margin	-27.87%	RSI (14)	53.45	Volatility	5.47% 4.69%
Employees	160	Debt/Eq	0.00	Sales Y/Y TTM	971120.00%	Profit Margin	-16.11%	Recom	1.00	Target Price	31.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-224.37%	Payout	0.00%	Rel Volume	0.75	Prev Close	13.44
Sales Surprise	6.57%	EPS Surprise	-3.46%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	1.71M	Price	14.49
SMA20	3.35%	SMA50	4.56%	SMA200	9.06%	Trades		Volume	1,273,175	Change	7.81%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
09:28AM	Loading…
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	Loading…
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
04:15PM	Loading…
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)
Sep-23-24 08:00AM	ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Aug-22-24 12:27AM	ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares (GuruFocus.com)
Aug-20-24 12:21PM	ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst (Benzinga)
Aug-15-24 07:02PM	Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY) (GuruFocus.com)
Aug-12-24 04:32AM	ARS Pharmaceuticals anaphylaxis nasal spray gains FDA approval (Pharmaceutical Technology)
Aug-09-24 01:34PM	FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment (Benzinga) +10.01%
12:49PM	ARS Pharmaceuticals Receives FDA Approval of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-07-24 09:01AM	ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-06-24 05:20PM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-28-24 06:30AM	ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire) +5.71%
May-12-24 09:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ... (GuruFocus.com)
May-09-24 11:54PM	SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 (InvestorPlace)
04:05PM	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 09:01AM	ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand (GlobeNewswire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 09:01AM	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) (GlobeNewswire)
Apr-01-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know (Zacks) -7.34%
Mar-26-24 08:50AM	Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why (Zacks) +9.53%
Mar-21-24 10:53PM	SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-15-24 06:00AM	Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 (InvestorPlace)
Mar-07-24 04:05PM	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day (GlobeNewswire)
Mar-06-24 09:01AM	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 09:01AM	ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study (GlobeNewswire)
Feb-22-24 09:01AM	ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024 (GlobeNewswire)
Feb-20-24 09:01AM	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter (GlobeNewswire)
Feb-05-24 09:01AM	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +8.75%
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Option Exercise	5.58	100,000	558,000	192,582	May 22 05:00 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Sale	14.10	102,969	1,451,513	89,613	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Option Exercise	1.01	120,000	121,200	120,000	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Sale	14.25	120,000	1,710,024	0	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Option Exercise	1.50	50,000	75,000	57,424	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Sale	14.10	50,000	705,165	7,424	May 22 05:00 PM
Scott Kathleen D.	Officer	May 20 '25	Proposed Sale	14.10	50,000	705,000		May 20 05:24 PM
Fitzpatrick Alexander A	Officer	May 20 '25	Proposed Sale	14.02	102,969	1,443,894		May 20 04:50 PM
SAUNDERS BRENT L	Director	May 20 '25	Proposed Sale	14.25	120,000	1,710,000		May 20 04:48 PM
Shawver Laura	Director	Apr 07 '25	Option Exercise	4.85	50,002	242,510	260,348	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Sale	12.30	50,002	615,075	210,346	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Proposed Sale	12.30	50,002	615,051		Apr 07 02:26 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Option Exercise	1.50	10,000	15,000	17,696	Mar 21 06:30 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Sale	14.00	10,000	140,000	7,696	Mar 21 06:30 PM
ERIC KARAS	Officer	Mar 20 '25	Proposed Sale	14.00	10,000	140,000		Mar 20 04:03 PM
Shawver Laura	Director	Mar 06 '25	Option Exercise	4.85	49,600	240,560	259,946	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Option Exercise	4.85	400	1,940	210,746	Mar 07 05:12 PM
Shawver Laura	Director	Mar 06 '25	Sale	11.21	49,600	556,046	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Sale	11.00	400	4,400	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Proposed Sale	11.00	50,000	550,000		Mar 05 05:19 PM
Shawver Laura	Director	Feb 03 '25	Option Exercise	4.54	50,000	227,091	260,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Sale	12.31	50,000	615,565	210,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Proposed Sale	12.31	50,000	615,565		Feb 03 12:06 PM
Shawver Laura	Director	Jan 06 '25	Option Exercise	3.15	50,000	157,500	260,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Sale	11.10	50,000	555,065	210,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Proposed Sale	11.10	50,000	555,065		Jan 06 04:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Option Exercise	0.84	117,333	98,560	253,713	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Option Exercise	1.44	27,272	39,272	163,652	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Sale	12.27	117,333	1,439,124	136,380	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Sale	12.06	27,272	328,968	136,380	Dec 13 07:53 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Option Exercise	0.64	25,000	16,000	31,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Option Exercise	0.64	15,000	9,600	21,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Sale	12.30	25,000	307,432	6,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Sale	12.43	15,000	186,426	6,024	Dec 13 07:52 PM
Chakma Justin	Officer	Dec 13 '24	Proposed Sale	12.06	27,272	328,967		Dec 13 05:24 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 12 05:41 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Sale	13.15	50,000	657,625	136,380	Dec 12 05:41 PM
Chakma Justin	Officer	Dec 10 '24	Proposed Sale	11.50	117,333	1,349,330		Dec 12 05:02 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Dorsey Brian	Officer	Dec 11 '24	Proposed Sale	13.31	61,200	814,572		Dec 11 05:31 PM
Chakma Justin	Director	Dec 10 '24	Proposed Sale	14.02	50,000	701,000		Dec 10 04:48 PM
Lowenthal Richard E	Officer	Dec 10 '24	Proposed Sale	13.40	300,000	4,020,000		Dec 10 11:15 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:43 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:43 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:25 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Option Exercise	0.84	49,640	41,698	186,020	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Sale	14.23	50,000	711,615	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Sale	14.13	49,640	701,642	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Sale	13.95	45,000	627,944	136,380	Dec 06 07:15 PM
Chakma Justin	Officer	Dec 06 '24	Proposed Sale	14.00	50,000	700,000		Dec 06 05:30 PM
Chakma Justin	Officer	Dec 05 '24	Proposed Sale	13.32	49,640	661,205		Dec 05 05:06 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Sale	13.67	45,000	615,218	136,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Sale	13.19	45,000	593,402	136,380	Dec 04 09:45 PM
Shawver Laura	Director	Dec 03 '24	Option Exercise	2.60	87,984	229,010	298,330	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Option Exercise	1.27	97,244	123,500	307,590	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Option Exercise	3.15	14,772	46,532	225,118	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Sale	13.56	97,244	1,318,745	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 03 '24	Sale	13.26	87,984	1,166,897	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Sale	13.75	14,772	203,109	210,346	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Option Exercise	1.50	6,283	9,424	11,976	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Option Exercise	1.50	3,717	5,576	9,410	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Sale	14.00	6,283	87,962	5,693	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Sale	14.11	3,717	52,461	5,693	Dec 04 09:40 PM
ERIC KARAS	Officer	Dec 04 '24	Proposed Sale	14.00	6,283	87,962		Dec 04 05:46 PM
Chakma Justin	Officer	Dec 04 '24	Proposed Sale	14.51	45,000	652,950		Dec 04 05:15 PM
Chakma Justin	Officer	Dec 03 '24	Proposed Sale	13.00	45,000	585,000		Dec 03 05:25 PM
Chakma Justin	Officer	Dec 02 '24	Proposed Sale	14.51	45,000	652,950		Dec 02 07:01 PM
Shawver Laura	Director	Dec 02 '24	Proposed Sale	13.56	200,000	2,713,000		Dec 02 06:22 PM
ERIC KARAS	Officer	Dec 02 '24	Proposed Sale	14.11	3,717	52,461		Dec 02 04:42 PM
Chakma Justin	Chief Business Officer	Nov 26 '24	Sale	14.05	42,186	592,570	161,380	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 25 '24	Sale	14.00	32,814	459,422	203,566	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 27 '24	Sale	14.39	25,000	359,750	136,380	Nov 27 04:11 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Chakma Justin	Officer	Nov 15 '24	Proposed Sale	17.30	236,380	4,089,374		Nov 15 03:21 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Flynn James E	10% Owner	Nov 11 '24	Sale	18.04	528,456	9,534,642	5,274,735	Nov 13 08:16 PM
Flynn James E	10% Owner	Nov 12 '24	Sale	17.49	34,814	609,064	5,257,328	Nov 13 08:16 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Option Exercise	1.50	12,500	18,750	17,449	Oct 17 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Sale	16.00	12,500	200,000	4,949	Oct 17 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
KATHLEEN D SCOTT	Officer	Oct 16 '24	Proposed Sale	16.00	12,500	200,000		Oct 16 04:01 PM
Tanimoto Sarina	Officer	Oct 15 '24	Proposed Sale	14.00	300,000	4,200,000		Oct 15 11:28 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:28 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:27 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Option Exercise	1.50	10,000	15,000	15,693	Sep 19 04:30 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Sale	14.00	10,000	140,000	5,693	Sep 19 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:29 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:26 PM
ERIC KARAS	Officer	Sep 18 '24	Proposed Sale	14.00	10,000	140,000		Sep 18 04:06 PM

Dollar change 0.00
Percentage change 0.00	%

SKIN Beauty Health Company daily Stock Chart

Peers: EL ULTA COTY LB SBH NUS VRME IRWD VICI EPC

| Held by: IWM VTI VXF IWO VDC SCHA JSML VTWO IWC GSSC

Index	RUT	P/E	-	EPS (ttm)	-0.41	Insider Own	41.36%	Shs Outstand	125.25M	Perf Week	-1.84%
Market Cap	201.62M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	0.00%	Shs Float	73.89M	Perf Month	12.68%
Income	-38.52M	PEG	-	EPS next Q	-0.05	Inst Own	56.50%	Short Float	10.90%	Perf Quarter	23.08%
Sales	322.47M	P/S	0.63	EPS this Y	1.09%	Inst Trans	-2.85%	Short Ratio	9.88	Perf Half Y	11.89%
Book/sh	0.37	P/B	4.35	EPS next Y	40.11%	ROA	-5.07%	Short Interest	8.05M	Perf Year	-24.17%
Cash/sh	2.96	P/C	0.54	EPS next 5Y	9.59%	ROE	-70.44%	52W Range	0.78 - 2.24	Perf YTD	0.63%
Dividend Est.	-	P/FCF	5.67	EPS past 5Y	-48.09%	ROI	-6.33%	52W High	-28.57%	Beta	1.17
Dividend TTM	-	Quick Ratio	6.43	Sales past 5Y	14.94%	Gross Margin	56.60%	52W Low	105.13%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	7.47	EPS Y/Y TTM	49.13%	Oper. Margin	-19.48%	RSI (14)	53.82	Volatility	3.12% 11.69%
Employees	769	Debt/Eq	12.33	Sales Y/Y TTM	-17.97%	Profit Margin	-11.94%	Recom	3.44	Target Price	1.76
Option/Short	Yes / Yes	LT Debt/Eq	12.21	EPS Q/Q	15.23%	Payout	-	Rel Volume	0.94	Prev Close	1.60
Sales Surprise	10.28%	EPS Surprise	37.60%	Sales Q/Q	-14.52%	Earnings	May 08 AMC	Avg Volume	815.20K	Price	1.60
SMA20	-2.97%	SMA50	21.70%	SMA200	7.05%	Trades		Volume	763,937	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-23	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Nov-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-14-23	Downgrade	The Benchmark Company	Buy → Hold
Nov-14-23	Downgrade	TD Cowen	Outperform → Market Perform	$9 → $2.50
Nov-14-23	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-14-23	Downgrade	Piper Sandler	Overweight → Underweight	$12 → $2
Nov-14-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-23	Downgrade	Canaccord Genuity	Buy → Hold	$10 → $2.50
Aug-25-23	Resumed	Canaccord Genuity	Buy	$10
Jun-21-23	Downgrade	Stifel	Buy → Hold	$17 → $10
Mar-20-23	Upgrade	Exane BNP Paribas	Underperform → Neutral
Nov-09-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $11
Mar-11-22	Initiated	JP Morgan	Overweight	$24
Jan-07-22	Initiated	William Blair	Outperform
Dec-23-21	Initiated	Raymond James	Mkt Perform
Oct-08-21	Initiated	Stifel	Buy	$33
Oct-04-21	Initiated	Cowen	Outperform	$32
Jul-19-21	Initiated	Jefferies	Buy	$22
Jul-01-21	Initiated	Goldman	Buy	$31
Jun-28-21	Reiterated	The Benchmark Company	Buy	$16 → $22

Show Previous Ratings

Jun-04-25 08:00AM	BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments (GlobeNewswire)
May-21-25 08:00AM	The Beauty Health Company Announces Convertible Debt Refinancing (GlobeNewswire) -7.69%
May-13-25 09:16AM	Beauty Health (SKIN) Reliance on International Sales: What Investors Need to Know (Zacks) -16.48%
May-09-25 03:43AM	The Beauty Health Co (SKIN) Q1 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... (GuruFocus.com) +50.81%
May-08-25 07:30PM	Beauty Health (SKIN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks) -12.68%
06:05PM	Loading…
06:05PM	The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BeautyHealth Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:35PM	The Beauty Health Q1 2025 Earnings Preview (Seeking Alpha) +35.24%
11:27AM	What To Expect From The Beauty Health Co (SKIN) Q1 2025 Earnings (GuruFocus.com)
May-05-25 12:42AM	3 Volatile Stocks Walking a Fine Line (StockStory) -7.02%
May-02-25 07:15AM	BrightSpring Health Services, Inc. (BTSG) Q1 Earnings and Revenues Beat Estimates (Zacks) +10.68%
Apr-29-25 04:00PM	BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-23-25 05:01AM	3 Reasons to Avoid SKIN and 1 Stock to Buy Instead (StockStory) +6.29%
Apr-05-25 09:49AM	3 Small-Cap Stocks with Mounting Challenges (StockStory)
Mar-18-25 05:07AM	Unpacking Q4 Earnings: BeautyHealth (NASDAQ:SKIN) In The Context Of Other Personal Care Stocks (StockStory)
03:08AM	Loading…
Mar-13-25 03:08AM	The Beauty Health Co (SKIN) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -5.63%
Mar-12-25 04:05PM	BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results (GlobeNewswire)
Mar-04-25 04:05PM	BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) -9.02% +11.21%
Dec-17-24 04:30PM	BeautyHealth Appoints Stephen J. Fanning to Board of Directors (Business Wire) -12.42%
Dec-11-24 08:00AM	BeautyHealth Releases 2024 Skintuition Report (Business Wire)
Nov-13-24 02:18AM	The Beauty Health Co (SKIN) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +8.82%
Nov-12-24 04:05PM	BeautyHealth Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-08-24 08:00AM	BeautyHealth to Report Third Quarter 2024 Financial Results on November 12, 2024 (Business Wire)
Oct-17-24 03:28PM	Hydrafacial Announces Video Poster Abstract Presentation at the 2024 American Society for Dermatologic Surgerys Annual Meeting (ASDS): Hydrafacial enhances the outcomes of non-ablative laser and IPL treatments (Business Wire)
Oct-15-24 04:10PM	The Beauty Health Company Strengthens Commercial Leadership Team with Chief Revenue Officer and Chief Marketing Officer Appointments (Business Wire)
10:51AM	Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians (Business Wire)
Oct-01-24 08:00AM	Hydrafacial Launches New Hydralock HA Booster with Clinically Proven Results (Business Wire)
Aug-08-24 04:35PM	BeautyHealth (NASDAQ:SKIN) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops 22.5% (StockStory) -13.18%
04:05PM	BeautyHealth Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-30-24 08:00AM	BeautyHealth to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
12:45PM	Loading…
May-10-24 12:45PM	The Beauty Health Company (NASDAQ:SKIN) Q1 2024 Earnings Call Transcript (Insider Monkey) -23.68%
May-09-24 06:30PM	Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings (Zacks)
06:10PM	The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:40PM	BeautyHealth (NASDAQ:SKIN) Beats Q1 Sales Targets But Quarterly Guidance Underwhelms (StockStory)
04:05PM	BeautyHealth Reports First Quarter 2024 Financial Results (Business Wire)
Apr-26-24 08:00AM	BeautyHealth to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) +5.88%
Apr-09-24 04:10PM	BeautyHealth Names Sheri Lewis as Chief Supply Chain and Operations Officer (Business Wire)
Mar-28-24 01:38PM	15 Best Beauty Stocks To Invest In (Insider Monkey)
04:45AM	Should You Sell The Beauty Health Company (SKIN)? (Insider Monkey)
Mar-13-24 09:02AM	The Beauty Health Company (NASDAQ:SKIN) Q4 2023 Earnings Call Transcript (Insider Monkey) +18.38%
Mar-12-24 05:32PM	The Beauty Health Co Reports Mixed 2023 Financial Results Amidst Global Expansion (GuruFocus.com)
04:10PM	BeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results (Business Wire)
04:05PM	BeautyHealth Announces Appointment Of Marla Beck As Chief Executive Officer (Business Wire)
Feb-29-24 04:06PM	BeautyHealth To Now Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (Business Wire) +12.01%
Feb-27-24 04:05PM	BeautyHealth to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 (Business Wire) +9.00%
Jan-13-24 02:04PM	Analyst Sees Further Downside for The Beauty Health Co. (SKIN) Amid Investor Suit Arising from Syndeo Mistakes Hagens Berman (GlobeNewswire)
Jan-10-24 11:30AM	BEAUTY HEALTH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Beauty Health To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-07-24 10:54AM	Beauty Health Company (SKIN) Faces Investor Lawsuit for Allegedly Concealing Syndeo's Frequent Treatment Interruptions Hagens Berman (GlobeNewswire)
Jan-01-24 09:38AM	Analyst Sees Further Downside For The Beauty Health Co. (SKIN) Amid Investor Suit Arising from Syndeo Mistakes Hagens Berman (GlobeNewswire)
Dec-29-23 01:53PM	Investors Allege Beauty Health Company (SKIN) Concealed Syndeo's Frequent Treatment Interruptions Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	BEAUTY HEALTH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Beauty Health To Contact Him Directly To Discuss Their Options (GlobeNewswire) -9.26%
Dec-25-23 11:06AM	Analyst Sees Further Downside For The Beauty Health Co. (SKIN) Amid Investor Suit Arising from Syndeo Mistakes Hagens Berman (GlobeNewswire)
Dec-22-23 02:15PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Beauty Health Company (SKIN) Investors Who Suffered Substantial Losses to Contact Firm, Securities Fraud Lawsuit Pending (GlobeNewswire)
Dec-19-23 12:41AM	Robbins LLP Reminds Investors of Lawsuit Against The Beauty Health Company and Approaching Lead Plaintiff Deadline (GlobeNewswire) +11.66%
Dec-18-23 04:03PM	Beauty Health Company (SKIN) Concealed Syndeo's Frequent Treatment Interruptions, Lawsuit Alleges Hagens Berman (GlobeNewswire)
Dec-12-23 08:00AM	BeautyHealth 2023 Skintuition Report: The Skin Health Trends and Data Shaping the Year (Business Wire)
Dec-11-23 12:14PM	Beauty Health Company (SKIN) Concealed Syndeo's Frequent Treatment Interruptions, Lawsuit Alleges Hagens Berman (GlobeNewswire)
Dec-08-23 01:24PM	Investors Allege Beauty Health Company (SKIN) Concealed Syndeo's Frequent Treatment Interruptions Hagens Berman (GlobeNewswire)
Dec-05-23 05:35PM	SKIN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that The Beauty Health Company Investors with Substantial Losses Have Opportunity to Lead Case (Business Wire) -5.70% +5.69%
Dec-01-23 01:28PM	Investors Say the Beauty Health Company (SKIN) Concealed Issues with Syndeo Devices Hagens Berman (GlobeNewswire) +11.33%
Nov-27-23 09:10AM	Beauty Health Company (SKIN) Faces Lawsuit Over Allegedly Concealing Issues with Syndeo Devices Hagens Berman (GlobeNewswire)
Nov-21-23 04:15PM	Investors Say the Beauty Health Company (SKIN) Concealed Issues with Syndeo Devices Hagens Berman (GlobeNewswire)
Nov-20-23 04:28PM	The Beauty Health Company investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-17-23 08:35PM	Lost Money in The Beauty Health Company? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) +26.97%
07:29PM	Investors Say the Beauty Health Company (SKIN) Concealed Issues with Syndeo Devices Hagens Berman (GlobeNewswire)
Nov-14-23 11:57AM	Why BeautyHealth (SKIN) Shares Are Sliding Today (StockStory) -64.36%
08:42AM	The Beauty Health Company (NASDAQ:SKIN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:43PM	The Beauty Health Co (SKIN) Faces Headwinds: Q3 Earnings Reveal Challenges and Revised Guidance (GuruFocus.com) +8.33%
04:10PM	BeautyHealth Reports Third Quarter 2023 Financial Results (Business Wire)
04:05PM	BeautyHealth Announces Leadership Transition (Business Wire)
Nov-07-23 06:12PM	BeautyHealth to Report Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire) -5.61%
08:00AM	Hydrafacial and Dr. Dennis Gross Skincare Unveil Phyto-Retinol Booster for the Treatment Room (Business Wire)
Nov-01-23 08:00AM	Save and Glow: New MyBeautyHealth App Offers Consumer Loyalty Rewards on Every Hydrafacial Treatment (Business Wire)
Oct-30-23 08:00AM	BeautyHealth Launches Hydrafacial Tmall Store in China in First Direct to Consumer Commercial Play (Business Wire) -5.51%
Oct-10-23 08:00AM	BeautyHealth Supports Next Generation of Estheticians with Hydrafacial School Partner Program (Business Wire) +5.02%
Oct-02-23 08:00AM	BeautyHealth Brings Hydrafacial Syndeo to New Cowshed Spas at Soho House Location in the U.S. (Business Wire)
Sep-20-23 08:00AM	BeautyHealth to Initiate Stock Repurchase Program, Following Recent $100 Million Share Repurchase Authorization (Business Wire)
Sep-12-23 09:00AM	BeautyHealth Announces Business Transformation Program to Drive Profitability and Growth; Board of Directors Authorizes $100 Million Share Repurchase (Business Wire) +23.58%
Sep-07-23 08:32AM	BeautyHealth Opens Exclusive Hydrafacial Pop-Up Treatment Suites in Harrods (Business Wire)
Aug-25-23 09:42AM	Netflix upgraded, Olaplex downgraded: Wall Street's top analyst calls (The Fly)
Aug-24-23 08:00AM	BeautyHealth Expands In-Store Hydrafacial Treatments to Sephora Australia (Business Wire)
Aug-22-23 08:00AM	30,000 Hydrafacial Devices and Counting: BeautyHealths Flagship Brand Reaches New Milestone (Business Wire)
Aug-09-23 07:30AM	BeautyHealth Reports Second Quarter 2023 Financial Results (Business Wire) -5.44%
07:25AM	BeautyHealth Names Michael Monahan Chief Financial Officer (Business Wire)
Aug-04-23 08:00AM	BeautyHealth Partners with LaserAway® to Supply Hydrafacial Syndeo Devices to All U.S. Locations (Business Wire)
Aug-02-23 08:00AM	BeautyHealths SkinStylus Receives New FDA Clearance for Facial Acne Scarring (Business Wire)
Jul-26-23 08:00AM	BeautyHealth to Report Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-17-23 08:00AM	Hydrafacial Debuts Custom Syndeo Device on Dior Spa Cruise 2023 (Business Wire)
May-23-23 08:00AM	BeautyHealth to Participate in TD Cowens 7th Annual Future of the Consumer Conference (Business Wire)
May-15-23 08:30AM	BeautyHealths Hydrafacial Announces Reimagined GLOWvolution Tour (Business Wire) +5.17%
May-10-23 07:30AM	BeautyHealth Reports First Quarter 2023 Financial Results (Business Wire) -6.73%
May-01-23 08:00AM	BeautyHealth Rings in Second Year as a Public Company with NASDAQ Opening Bell Ceremony (Business Wire)
Apr-26-23 08:00AM	BeautyHealth to Report First Quarter 2023 Financial Results on May 10, 2023 (Business Wire)
Apr-19-23 04:30PM	Maturing into a Multi-Brand Ecosystem, BeautyHealth Appoints Aesthetics Veteran Brad Hauser as Chief Operating Officer (Business Wire)
Apr-17-23 08:00PM	BeautyHealths Hydrafacial Opens New Beijing Experience Center, Signaling Continued Investment in High-Growth China Market (Business Wire)
Mar-30-23 04:00AM	Revolutionizing the Treatment Room: BeautyHealth Launches Connected Hydrafacial Syndeo Device in Europe and Asia (Business Wire)
Feb-28-23 07:30AM	BeautyHealth Reports Full Year and Fourth Quarter 2022 Financial Results (Business Wire) +11.40%
07:15AM	BeautyHealth to Acquire SkinStylus®, FDA-Cleared Microneedling Device (Business Wire)
Feb-27-23 08:00AM	Dior Powered by Hydrafacial (Business Wire)
Feb-21-23 12:01AM	BeautyHealths Hydrafacial and Prestige Skincare Brand Omorovicza Announce Global Launch of Advanced Skin Renewal Booster (Business Wire)

The Beauty Health Co. engages in the design, development, manufacture, marketing, and sale of esthetic technologies and products. Its brands include Hydrafacial, SkinStylus, and Keravive. The company was founded in 1997 and is headquartered in Long Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gruber Desiree	Director	Nov 20 '24	Sale	1.50	14,663	22,022	119,514	Nov 21 04:48 PM
SAUNDERS BRENT L	Chairman	Aug 12 '24	Buy	1.08	40,450	43,686	5,921,769	Aug 13 05:00 PM

BLCO

Bausch + Lomb Corp

SPRY

ARS Pharmaceuticals Inc

SKIN

Beauty Health Company

Upgrade your FINVIZ experience